Forest Laboratories to Acquire Furiex Pharmaceuticals for $1.1 Billion in Cash to Build on a Leading Position in Gastroenterology (GI)

Deal Also Includes Up to $30 per share in a Contingent Value Right for Furiex Shareholders

Creates a Leading GI Company within Forest
- Acquisition Adds Global Rights to Eluxadoline
- New Drug Application Expected to be Filed in 2014
- Eluxadoline is Complementary to Linzess for IBS-C and CIC and Additive to Forest’s GI Treatments Acquired in Acquisition of Aptalis

Forest to Partner with Royalty Pharma by Divesting Furiex’s Royalty Rights on Alogliptin and Priligy®

Sarepta Therapeutics Announces Plans to Submit New Drug Application to FDA for Eteplirsen for the Treatment of Duchenne Muscular Dystrophy by Year End 2014

-- FDA provides updated guidance on potential early approval pathway for eteplirsen;
-- Agreement reached with the Agency on eteplirsen open-label confirmatory studies with enrollment of a broader base of DMD patients later this year;
-- FDA provides initial guidance on development of follow-on DMD drug candidates;
-- Company to hold teleconference at 8:00 a.m. EDT

Epirus and Zalicus Announce Merger Agreement

• Merger will create a publicly traded, global biosimilar enterprise focused on improving patient access to important medicines

• Epirus closes $36 million Series B financing round

• Management to Hold Conference Call at 8:30 a.m. EDT

Epirus Biopharmaceuticals, Inc. (Epirus), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, and Zalicus Inc. (ZLCS) (Zalicus), announced today that they have entered into a definitive agreement under which Epirus will merge with a wholly-owned subsidiary of Zalicus in an all-stock transaction.